Lucas Bouys
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucas Bouys has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Jérôme Bertherat
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
11 shared publications - Florian Violon
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
7 shared publications - Annabel Berthon
Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA
6 shared publications Anne Jouinot
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
6 shared publicationsKarine Perlemoine
Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France
6 shared publicationsLaurence Guignat
Department of Endocrinology and National Reference Center for Rare Adrenal Disorders, AP-HP, Hôpital Cochin, Paris, France
6 shared publications
Latest Publications
- 5 October 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (4) , 667-676
Diagnostic utility of diurnal salivary cortisol profiles in neoplastic and nonneoplastic hypercortisolism
Objective: Salivary cortisol has the advantages of being noninvasive, readily accessible in ambulatory patients and reflecting the free bioactive fraction of cortisol. The cortisol diurnal cycle, based on 6 samples collected every 4 h over a 24-h period, allows a detailed characterization of cortisol variations throughout the day. The objective of this study was to assess the value of the salivary cortisol diurnal cycle for the diagnosis of Cushing's syndrome (CS) and the differential diagnosis of nonneoplastic hypercortisolism. Design: This retrospective cohort study included all the patients hospitalized in Endocrinology department of Cochin Hospital between 2012 and 2018 who had complete serum and salivary diurnal cycle assessments. Methods: Serum and salivary cortisol levels were measured using an automated and a radio immunoassay, respectively. Results: A total of 227 subjects without CS, 46 patients with nonneoplastic CS, 72 patients with ACTH-dependent CS, and 67 with adrenal CS were included. For the diagnosis of CS, the cortisol nadir throughout the day showed better diagnostic performance than midnight cortisol, both in serum and saliva with, area under the receiver operating characteristic curves (ROC AUCs) of 0.98 and of 0.96, respectively. For the differential diagnosis between nonneoplastic hypercortisolism and ACTH-dependent CS, salivary cortisol showed better diagnostic performance than midnight serum cortisol (ROC AUC 0.97; optimal cutoff 5.3 nM; sensitivity 90%; and specificity 87% for the salivary cortisol nadir). Conclusion: The salivary cortisol diurnal cycle appears to be a powerful tool for the diagnosis of CS and for the challenging differential diagnosis of nonneoplastic hypercortisolism, with the major advantage of being accessible in ambulatory patients.
- 5 October 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (4) , 667-676
Diagnostic utility of diurnal salivary cortisol profiles in neoplastic and nonneoplastic hypercortisolism
Objective: Salivary cortisol has the advantages of being noninvasive, readily accessible in ambulatory patients and reflecting the free bioactive fraction of cortisol. The cortisol diurnal cycle, based on 6 samples collected every 4 h over a 24-h period, allows a detailed characterization of cortisol variations throughout the day. The objective of this study was to assess the value of the salivary cortisol diurnal cycle for the diagnosis of Cushing's syndrome (CS) and the differential diagnosis of nonneoplastic hypercortisolism. Design: This retrospective cohort study included all the patients hospitalized in Endocrinology department of Cochin Hospital between 2012 and 2018 who had complete serum and salivary diurnal cycle assessments. Methods: Serum and salivary cortisol levels were measured using an automated and a radio immunoassay, respectively. Results: A total of 227 subjects without CS, 46 patients with nonneoplastic CS, 72 patients with ACTH-dependent CS, and 67 with adrenal CS were included. For the diagnosis of CS, the cortisol nadir throughout the day showed better diagnostic performance than midnight cortisol, both in serum and saliva with, area under the receiver operating characteristic curves (ROC AUCs) of 0.98 and of 0.96, respectively. For the differential diagnosis between nonneoplastic hypercortisolism and ACTH-dependent CS, salivary cortisol showed better diagnostic performance than midnight serum cortisol (ROC AUC 0.97; optimal cutoff 5.3 nM; sensitivity 90%; and specificity 87% for the salivary cortisol nadir). Conclusion: The salivary cortisol diurnal cycle appears to be a powerful tool for the diagnosis of CS and for the challenging differential diagnosis of nonneoplastic hypercortisolism, with the major advantage of being accessible in ambulatory patients.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Génétique de l'hyperplasie macronodulaire bilatérale des surrénales : ARMC5 et KDM1A
Contexte : L'Hyperplasie Macronodulaire Bilatérale des Surrénales (HMBS) est une maladie rare caractérisée par des macronodules surrénaliens bilatéraux, potentiellement responsables d'un hypercortisolisme (syndrome de Cushing). Une première cause génétique a été identifiée en 2013 : des mutations constitutionnelles inactivatrices hétérozygotes du gène suppresseur de tumeur ARMC5, responsable de 20 à 25% des cas. L'atteinte surrénalienne bilatérale et la description de cas familiaux sans mutation d'ARMC5 suggèrent l'existence d'autres facteurs de prédisposition génétique. L'HMBS est une pathologie hétérogène sur les plans clinique, biologique et radiologique et dont la présentation varie des incidentalomes surrénaliens bilatéraux sans hypercortisolisme clinique à un élargissement massif des surrénales associé à une syndrome de Cushing sévère. Objectifs : Comprendre l'hétérogénéité clinique de l'HMBS, identifier de nouveaux gènes de prédisposition, mieux caractériser les patients sur les plans clinique, biologique et radiologique. Méthodes : Les données cliniques de 352 patients index européens ont été collectées rétrospectivement pour la corrélation génotype/phénotype, l'ensemble des variations d'ARMC5 a été recensé, incluant celles décrites dans la littérature et celles identifiées dans notre centre. Une analyse multi-omique, associant RNAseq, méthylome, miRNome, exome et SNP array, a été réalisée sur les échantillons surrénaliens de 36 patients opérés pour une HMBS. Résultats : L'analyse de la série de 352 patients génotypés pour ARMC5 confirme que les patients mutés ont un phénotype plus marqué que les patients non mutés, en termes de sévérité du syndrome de Cushing et de l'atteinte surrénalienne. 100% des patients mutés ont une atteinte surrénalienne bilatérale claire en imagerie et au moins un hypercortisolisme modéré, défini par un cortisol après freinage par la dexaméthasone supérieur à 50 nmol/L, alors que ces critères sont inconstants chez les patients non mutés. L'association de ces 2 critères a une sensibilité de 100% pour la détection d'une mutation d'ARMC5. Nous proposons que le génotypage d'ARMC5 soit réservé aux patients présentant ces deux critères simples afin d'augmenter le rendement du séquençage, avec un taux de mutation de 20%. Nous présentons 133 mutations constitutionnelles différentes d'ARMC5, dont 50 jamais décrites dans la littérature, représentées majoritairement par des variants non-sens, faux-sens, et des insertions/délétions avec décalage du cadre de lecture. L'évaluation de la pathogénicité des variants faux-sens est parfois difficile, et se base sur leur fréquence en population, leur ségrégation dans les cas familiaux, les prédictions in silico, et les études fonctionnelles disponibles. Nos données fonctionnelles permettent une meilleure classification de nombreux variants faux-sens. L'analyse intégrée des données de génomique des échantillons de 36 patients HMBS révèle trois groupes moléculaires distincts : G1, comprenant les tumeurs des 16 patients porteurs d'une mutation d'ARMC5 ; G2, les tumeurs des 6 patients présentant un syndrome de Cushing dépendant de l'alimentation, médié par l'expression illégitime du récepteur du GIP par les cellules corticosurrénaliennes ; et G3, les tumeurs des autres patients avec phénotype plus hétérogène. L'analyse de l'exome identifie des mutations constitutionnelles inactivatrices hétérozygotes du gène KDM1A chez 5/6 patients du G2, constamment associées à une perte d'hétérozygotie dans la surrénale du bras 1p portant le locus KDM1A, aboutissant à une inactivation biallélique du gène. Conclusion : Ces travaux permettent une meilleure caractérisation des patients porteurs d'HMBS, l'identification de critères prédictifs d'une mutation d'ARMC5, une meilleure compréhension de l'hétérogénéité clinique de l'HMBS et la découverte de la cause génétique de l'HMBS associée à un syndrome de Cushing dépendant de l'alimentation : le gène suppresseur de tumeur KDM1A.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Génétique de l'hyperplasie macronodulaire bilatérale des surrénales : ARMC5 et KDM1A
Contexte : L'Hyperplasie Macronodulaire Bilatérale des Surrénales (HMBS) est une maladie rare caractérisée par des macronodules surrénaliens bilatéraux, potentiellement responsables d'un hypercortisolisme (syndrome de Cushing). Une première cause génétique a été identifiée en 2013 : des mutations constitutionnelles inactivatrices hétérozygotes du gène suppresseur de tumeur ARMC5, responsable de 20 à 25% des cas. L'atteinte surrénalienne bilatérale et la description de cas familiaux sans mutation d'ARMC5 suggèrent l'existence d'autres facteurs de prédisposition génétique. L'HMBS est une pathologie hétérogène sur les plans clinique, biologique et radiologique et dont la présentation varie des incidentalomes surrénaliens bilatéraux sans hypercortisolisme clinique à un élargissement massif des surrénales associé à une syndrome de Cushing sévère. Objectifs : Comprendre l'hétérogénéité clinique de l'HMBS, identifier de nouveaux gènes de prédisposition, mieux caractériser les patients sur les plans clinique, biologique et radiologique. Méthodes : Les données cliniques de 352 patients index européens ont été collectées rétrospectivement pour la corrélation génotype/phénotype, l'ensemble des variations d'ARMC5 a été recensé, incluant celles décrites dans la littérature et celles identifiées dans notre centre. Une analyse multi-omique, associant RNAseq, méthylome, miRNome, exome et SNP array, a été réalisée sur les échantillons surrénaliens de 36 patients opérés pour une HMBS. Résultats : L'analyse de la série de 352 patients génotypés pour ARMC5 confirme que les patients mutés ont un phénotype plus marqué que les patients non mutés, en termes de sévérité du syndrome de Cushing et de l'atteinte surrénalienne. 100% des patients mutés ont une atteinte surrénalienne bilatérale claire en imagerie et au moins un hypercortisolisme modéré, défini par un cortisol après freinage par la dexaméthasone supérieur à 50 nmol/L, alors que ces critères sont inconstants chez les patients non mutés. L'association de ces 2 critères a une sensibilité de 100% pour la détection d'une mutation d'ARMC5. Nous proposons que le génotypage d'ARMC5 soit réservé aux patients présentant ces deux critères simples afin d'augmenter le rendement du séquençage, avec un taux de mutation de 20%. Nous présentons 133 mutations constitutionnelles différentes d'ARMC5, dont 50 jamais décrites dans la littérature, représentées majoritairement par des variants non-sens, faux-sens, et des insertions/délétions avec décalage du cadre de lecture. L'évaluation de la pathogénicité des variants faux-sens est parfois difficile, et se base sur leur fréquence en population, leur ségrégation dans les cas familiaux, les prédictions in silico, et les études fonctionnelles disponibles. Nos données fonctionnelles permettent une meilleure classification de nombreux variants faux-sens. L'analyse intégrée des données de génomique des échantillons de 36 patients HMBS révèle trois groupes moléculaires distincts : G1, comprenant les tumeurs des 16 patients porteurs d'une mutation d'ARMC5 ; G2, les tumeurs des 6 patients présentant un syndrome de Cushing dépendant de l'alimentation, médié par l'expression illégitime du récepteur du GIP par les cellules corticosurrénaliennes ; et G3, les tumeurs des autres patients avec phénotype plus hétérogène. L'analyse de l'exome identifie des mutations constitutionnelles inactivatrices hétérozygotes du gène KDM1A chez 5/6 patients du G2, constamment associées à une perte d'hétérozygotie dans la surrénale du bras 1p portant le locus KDM1A, aboutissant à une inactivation biallélique du gène. Conclusion : Ces travaux permettent une meilleure caractérisation des patients porteurs d'HMBS, l'identification de critères prédictifs d'une mutation d'ARMC5, une meilleure compréhension de l'hétérogénéité clinique de l'HMBS et la découverte de la cause génétique de l'HMBS associée à un syndrome de Cushing dépendant de l'alimentation : le gène suppresseur de tumeur KDM1A.
- Open Access
- 4 March 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (3) , 381-392
Clinical predictors of outcome in advanced adrenocortical carcinoma: a multicenter international ENSAT study
Objective: Advanced adrenocortical carcinoma (ACC) is treated with mitotane alone or combined with cytotoxic chemotherapy, yet outcomes remain poor and prognostic models in this setting are lacking. This study aimed to evaluate the prognostic value of clinical parameters in a large cohort of patients with advanced ACC undergoing systemic therapy. Methods: Multicenter, international cohort study investigating 418 patients with advanced ACC (61.5% = women, median age = 52 years) from 11 centers. Patients received mitotane monotherapy (n = 161), etoposide + doxorubicin + cisplatin ± mitotane (n = 178), or second-line regimens (gemcitabine + capecitabine ± mitotane or temozolomide + mitotane, n = 79). Variables included age, cortisol excess, performance status (ECOG-PS), tumor burden, and neutrophil-to-lymphocyte ratio (NLR) at start of therapy. Outcomes were overall survival (OS), time to progression (TTP), and best objective response. Results: Tumor burden, cortisol excess, ECOG-PS, and NLR ≥5 independently predicted shorter OS (hazard ratio [HR] 1.55-2.68). We developed an integrated ENSAT Risk Score for Advanced ACC combining these variables: tumor burden (0-2), cortisol excess (0/1), ECOG-PS (0-2), and NLR (0/1). A score >2 (poor-risk) was significantly associated with worse OS and TTP across all treatment groups (HRs for OS: 3.05-3.96; TTP: 2.53-3.08). It also predicted poorer response to mitotane (P < .01) and second-line therapies (P = .04). Conclusions: The ENSAT Risk Score for Advanced ACC is a practical, prognostic tool for patients with advanced ACC receiving systemic therapy. Based on accessible clinical and biochemical markers, it can support treatment decisions and facilitate informed discussions in routine care.
- 4 March 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (3) , 381-392
Open AccessClinical predictors of outcome in advanced adrenocortical carcinoma: a multicenter international ENSAT study
Objective: Advanced adrenocortical carcinoma (ACC) is treated with mitotane alone or combined with cytotoxic chemotherapy, yet outcomes remain poor and prognostic models in this setting are lacking. This study aimed to evaluate the prognostic value of clinical parameters in a large cohort of patients with advanced ACC undergoing systemic therapy. Methods: Multicenter, international cohort study investigating 418 patients with advanced ACC (61.5% = women, median age = 52 years) from 11 centers. Patients received mitotane monotherapy (n = 161), etoposide + doxorubicin + cisplatin ± mitotane (n = 178), or second-line regimens (gemcitabine + capecitabine ± mitotane or temozolomide + mitotane, n = 79). Variables included age, cortisol excess, performance status (ECOG-PS), tumor burden, and neutrophil-to-lymphocyte ratio (NLR) at start of therapy. Outcomes were overall survival (OS), time to progression (TTP), and best objective response. Results: Tumor burden, cortisol excess, ECOG-PS, and NLR ≥5 independently predicted shorter OS (hazard ratio [HR] 1.55-2.68). We developed an integrated ENSAT Risk Score for Advanced ACC combining these variables: tumor burden (0-2), cortisol excess (0/1), ECOG-PS (0-2), and NLR (0/1). A score >2 (poor-risk) was significantly associated with worse OS and TTP across all treatment groups (HRs for OS: 3.05-3.96; TTP: 2.53-3.08). It also predicted poorer response to mitotane (P < .01) and second-line therapies (P = .04). Conclusions: The ENSAT Risk Score for Advanced ACC is a practical, prognostic tool for patients with advanced ACC receiving systemic therapy. Based on accessible clinical and biochemical markers, it can support treatment decisions and facilitate informed discussions in routine care.
- 12 January 2026
- Published by Springer Nature in Endocrine Pathology
- Vol. 37 (1) , 3
The Proteome of Bilateral Macronodular Adrenocortical Disease (BMAD) Shows Different Profiles Correlating with the Genetic Causes and Reveals Specific Dysregulation of RNA Polymerase II and Cholesterol Biosynthesis Enzymes
- 12 January 2026
- Published by Springer Nature in Endocrine Pathology
- Vol. 37 (1) , 3
The Proteome of Bilateral Macronodular Adrenocortical Disease (BMAD) Shows Different Profiles Correlating with the Genetic Causes and Reveals Specific Dysregulation of RNA Polymerase II and Cholesterol Biosynthesis Enzymes
- Open Access
- 6 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Impact of steroid differentiation on tumor microenvironment revealed by single-nucleus atlas of adrenal tumors
Adrenocortical carcinomas (ACC) are aggressive and resistant to medical treatment. This study reports a single-nucleus transcriptome atlas of steroid and microenvironment cells in 38 human normal adrenals and adrenocortical tumors. We identify intermediate-state cells between glomerulosa and fasciculata, a transition state in the centripetal trans-differentiation of normal steroid cells. In tumors, steroid cells show expression programs reflecting this zonation. Although ACC microenvironment is scarce, its signatures combine with those of steroid cells into ecotypes. A first ecotype combines cancer-associated fibroblasts, tumor-associated endothelial cells, with hypoxia and mitosis signatures in steroid cells. Another ecotype combines exhausted T cells, with fasciculata steroid signature. These ecotypes are associated with poor survival. Conversely, a third ecotype combines inflammatory macrophages, with reticularis steroid signature, and better outcome. These steroid/microenvironment cells interplays improve outcome predictions and may open therapeutic options in aggressive ACC, through immune microenvironment activation by modulating glucocorticoids/androgens balance.
- 6 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessImpact of steroid differentiation on tumor microenvironment revealed by single-nucleus atlas of adrenal tumors
Adrenocortical carcinomas (ACC) are aggressive and resistant to medical treatment. This study reports a single-nucleus transcriptome atlas of steroid and microenvironment cells in 38 human normal adrenals and adrenocortical tumors. We identify intermediate-state cells between glomerulosa and fasciculata, a transition state in the centripetal trans-differentiation of normal steroid cells. In tumors, steroid cells show expression programs reflecting this zonation. Although ACC microenvironment is scarce, its signatures combine with those of steroid cells into ecotypes. A first ecotype combines cancer-associated fibroblasts, tumor-associated endothelial cells, with hypoxia and mitosis signatures in steroid cells. Another ecotype combines exhausted T cells, with fasciculata steroid signature. These ecotypes are associated with poor survival. Conversely, a third ecotype combines inflammatory macrophages, with reticularis steroid signature, and better outcome. These steroid/microenvironment cells interplays improve outcome predictions and may open therapeutic options in aggressive ACC, through immune microenvironment activation by modulating glucocorticoids/androgens balance.
- 14 August 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (3) , e917-e926
A Global Approach to the Long-Term Follow-Up of 17 Families With Bilateral Macronodular Adrenal Disease
Context: Bilateral macronodular adrenocortical disease (BMAD) is a rare and often underdiagnosed cause of adrenal Cushing syndrome (CS), with manifestations ranging from mild autonomous cortisol secretion (MACS) to overt CS. ARMC5 and KDM1A are the most frequently implicated genes in familial BMAD; however, long-term follow-up data on affected patients remain limited. Objective: This retrospective study assessed the clinical and hormonal variability, genetic profiles, treatment approaches, and outcomes of 17 familial and 9 sporadic BMAD cases over a follow-up period ranging from 8 to 410 months at a Brazilian tertiary center. Methods: A total of 250 individuals (50 index cases and 200 relatives) were included. Clinical, hormonal, and imaging data, along with histological and genetic analyses of ARMC5 and KDM1A, were evaluated. Results: Among 250 individuals, 104 (26 index and 78 relatives) carried germline pathogenic/likely pathogenic ARMC5 variants. No KDM1A (likely) pathogenic variants were identified in ARMC5-wild-type patients. ARMC5-positive index cases exhibited severe clinical manifestations, evidenced by elevated cortisol levels (urinary, salivary, and post–dexamethasone suppression test) and reduced ACTH and DHEAS levels (P = .005, P = .042, P = .005, P = .041, and P = .007, respectively). Index cases had larger adrenal nodules (P < .0001). Adrenal-sparing surgery achieved 100% remission vs a 40% remission rate for unilateral adrenalectomy. Central nervous system meningiomas were observed in BMAD patients independent of ARMC5 status. Interestingly, malignant neoplasms were notably prevalent among ARMC5-altered individuals. Conclusion: The proposed management flowchart highlights the importance of genetic screening and continuous monitoring to mitigate the adrenal insufficiency, MACS recurrence, and tumor risk, while underscoring the need for tailored therapeutic strategies in BMAD, adapted to genetic alterations and ARMC5 status.
- 14 August 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (3) , e917-e926
A Global Approach to the Long-Term Follow-Up of 17 Families With Bilateral Macronodular Adrenal Disease
Context: Bilateral macronodular adrenocortical disease (BMAD) is a rare and often underdiagnosed cause of adrenal Cushing syndrome (CS), with manifestations ranging from mild autonomous cortisol secretion (MACS) to overt CS. ARMC5 and KDM1A are the most frequently implicated genes in familial BMAD; however, long-term follow-up data on affected patients remain limited. Objective: This retrospective study assessed the clinical and hormonal variability, genetic profiles, treatment approaches, and outcomes of 17 familial and 9 sporadic BMAD cases over a follow-up period ranging from 8 to 410 months at a Brazilian tertiary center. Methods: A total of 250 individuals (50 index cases and 200 relatives) were included. Clinical, hormonal, and imaging data, along with histological and genetic analyses of ARMC5 and KDM1A, were evaluated. Results: Among 250 individuals, 104 (26 index and 78 relatives) carried germline pathogenic/likely pathogenic ARMC5 variants. No KDM1A (likely) pathogenic variants were identified in ARMC5-wild-type patients. ARMC5-positive index cases exhibited severe clinical manifestations, evidenced by elevated cortisol levels (urinary, salivary, and post–dexamethasone suppression test) and reduced ACTH and DHEAS levels (P = .005, P = .042, P = .005, P = .041, and P = .007, respectively). Index cases had larger adrenal nodules (P < .0001). Adrenal-sparing surgery achieved 100% remission vs a 40% remission rate for unilateral adrenalectomy. Central nervous system meningiomas were observed in BMAD patients independent of ARMC5 status. Interestingly, malignant neoplasms were notably prevalent among ARMC5-altered individuals. Conclusion: The proposed management flowchart highlights the importance of genetic screening and continuous monitoring to mitigate the adrenal insufficiency, MACS recurrence, and tumor risk, while underscoring the need for tailored therapeutic strategies in BMAD, adapted to genetic alterations and ARMC5 status.
- 14 June 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (1) , 106-116
Unexpected discrepancies between steroid intra-tissular content in adrenal tumors and clinical diagnosis of steroid excess
Objective: Adrenocortical tumor (ACT) morbidity is associated with steroid secretion, depending on tumor type. Indeed, adrenal steroidogenesis is a finely regulated process, altered in ACT. These alterations are usually characterized by blood steroid assays, also depending on steroid gonadal production and metabolism. Our aim was to determine steroid content directly in ACT tissues and to compare it with clinical diagnosis of steroid excess. Methods: A profile of 13 steroids was analyzed in ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (Thermo Fisher Scientific®) in frozen tissue samples from 75 ACT, 7 Cushing's disease, and 9 normal adrenals. Results: Steroid levels were 10-1000 times higher in tissue from normal adrenal than normal concentrations expected in blood. Concentration ratios between tissue from normal adrenal and blood reference values were lower for distal products than for steroid precursors. In adrenocortical cancers, intra-tissular steroid content was lower than in unilateral benign tumors despite clear clinical steroid excess. Unexpectedly, in overt-Cushing adenomas, intra-tissular cortisol levels were not higher and androstenedione levels were not lower than in non-functioning adenomas. Adrenal differentiation score based on transcriptome was well correlated with intra-tissular cortisol levels. Conclusion: Discrepancies observed between steroid levels measured in ACT tissue and clinical diagnosis of steroid excess suggest a dysregulation of steroid export depending on tumor type, opening new perspectives for diagnosis and treatment of steroid excess.
- 14 June 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (1) , 106-116
Unexpected discrepancies between steroid intra-tissular content in adrenal tumors and clinical diagnosis of steroid excess
Objective: Adrenocortical tumor (ACT) morbidity is associated with steroid secretion, depending on tumor type. Indeed, adrenal steroidogenesis is a finely regulated process, altered in ACT. These alterations are usually characterized by blood steroid assays, also depending on steroid gonadal production and metabolism. Our aim was to determine steroid content directly in ACT tissues and to compare it with clinical diagnosis of steroid excess. Methods: A profile of 13 steroids was analyzed in ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (Thermo Fisher Scientific®) in frozen tissue samples from 75 ACT, 7 Cushing's disease, and 9 normal adrenals. Results: Steroid levels were 10-1000 times higher in tissue from normal adrenal than normal concentrations expected in blood. Concentration ratios between tissue from normal adrenal and blood reference values were lower for distal products than for steroid precursors. In adrenocortical cancers, intra-tissular steroid content was lower than in unilateral benign tumors despite clear clinical steroid excess. Unexpectedly, in overt-Cushing adenomas, intra-tissular cortisol levels were not higher and androstenedione levels were not lower than in non-functioning adenomas. Adrenal differentiation score based on transcriptome was well correlated with intra-tissular cortisol levels. Conclusion: Discrepancies observed between steroid levels measured in ACT tissue and clinical diagnosis of steroid excess suggest a dysregulation of steroid export depending on tumor type, opening new perspectives for diagnosis and treatment of steroid excess.
- 2 February 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 218, 115276
Letter Re: Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma
- 2 February 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 218, 115276
Letter Re: Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma
- 1 February 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (2) , 119-127
KDM1A genetic alterations, a rare cause of primary bilateral macronodular adrenal hyperplasia, strongly associated with food-dependent Cushing's syndrome: results of its systematic germline screening in 301 index cases and genotype/phenotype correlation
Objective: ARMC5 is the most prevalent gene predisposing to primary bilateral macronodular adrenal hyperplasia (PBMAH), but germline KDM1A variants have been identified in the rare PBMAH associated with food-dependent Cushing's syndrome (FDCS). The purpose of this work was to assess the frequency of KDM1A variants in a large series of PBMAH patients. Design: A total of 301 consecutive PBMAH index cases from 8 international endocrinology departments were included. Clinical, biological, and imaging data were collected retrospectively. Results: Ten (3.3%) patients carried a germline KDM1A pathogenic or likely pathogenic variant, 60 (19.9%) carried a germline ARMC5 alteration, and 231 (76.8%) had no identified genetic predisposition. Food-dependent Cushing's syndrome was present in all patients with KDM1A variants and absent in the 2 other groups. KDM1A patients had a higher 24-h urinary free cortisol (3.0-fold upper limit of normal vs 1.36 for ARMC5 patients and 0.66 for wild-type patients, respectively, P = .0001). In accordance with FDCS pathophysiology, patients with KDM1A variants had a lower morning fasting plasma cortisol (192 nmol/L vs 407 and 428, respectively, P = .0003) and a higher midnight plasma cortisol (487 nmol/L vs 297 and 171.96, respectively, P = .0004). Morning/midnight plasma cortisol ratio below 0.65 holds 100% sensitivity and specificity for the detection of FDCS. All patients with KDM1A variants were women, vs 65% of ARMC5 patients and 67% of wild-type patients (P = .0337). Conclusions: KDM1A germline pathogenic variants are rare in PBMAH and account for <5% of index cases. KDM1A seems constantly associated with FDCS, which can be evoked in front of a morning/midnight plasma cortisol ratio below 0.65.
- 1 February 2025
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 192 (2) , 119-127
KDM1A genetic alterations, a rare cause of primary bilateral macronodular adrenal hyperplasia, strongly associated with food-dependent Cushing's syndrome: results of its systematic germline screening in 301 index cases and genotype/phenotype correlation
Objective: ARMC5 is the most prevalent gene predisposing to primary bilateral macronodular adrenal hyperplasia (PBMAH), but germline KDM1A variants have been identified in the rare PBMAH associated with food-dependent Cushing's syndrome (FDCS). The purpose of this work was to assess the frequency of KDM1A variants in a large series of PBMAH patients. Design: A total of 301 consecutive PBMAH index cases from 8 international endocrinology departments were included. Clinical, biological, and imaging data were collected retrospectively. Results: Ten (3.3%) patients carried a germline KDM1A pathogenic or likely pathogenic variant, 60 (19.9%) carried a germline ARMC5 alteration, and 231 (76.8%) had no identified genetic predisposition. Food-dependent Cushing's syndrome was present in all patients with KDM1A variants and absent in the 2 other groups. KDM1A patients had a higher 24-h urinary free cortisol (3.0-fold upper limit of normal vs 1.36 for ARMC5 patients and 0.66 for wild-type patients, respectively, P = .0001). In accordance with FDCS pathophysiology, patients with KDM1A variants had a lower morning fasting plasma cortisol (192 nmol/L vs 407 and 428, respectively, P = .0003) and a higher midnight plasma cortisol (487 nmol/L vs 297 and 171.96, respectively, P = .0004). Morning/midnight plasma cortisol ratio below 0.65 holds 100% sensitivity and specificity for the detection of FDCS. All patients with KDM1A variants were women, vs 65% of ARMC5 patients and 67% of wild-type patients (P = .0337). Conclusions: KDM1A germline pathogenic variants are rare in PBMAH and account for <5% of index cases. KDM1A seems constantly associated with FDCS, which can be evoked in front of a morning/midnight plasma cortisol ratio below 0.65.
- 7 January 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e2946-e2955
PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series
Context: Primary bilateral macronodular adrenal hyperplasia (PBMAH), the most common cause of Cushing syndrome due to bilateral nodules, is a heterogeneous disease at the clinical, hormonal, and morphological levels. ARMC5-inactivating pathogenic variants are causative of PBMAH, and rare variants of PDE11A have been associated with PBMAH. Objective: The aim of this study, on a large cohort of individuals with PBMAH from Europe and America, was to study the ARMC5 and PDE11A genotype to determine the genotype/phenotype correlation and to investigate the hypothesis that PDE11A could be a modifying gene of the adrenal phenotype. Methods: Leukocyte DNA of 354 PBMAH index cases was sequenced for ARMC5 and PDE11A genes by next-generation sequencing. Phenotypic characteristics of 334 of these patients were analyzed to study the genotype/phenotype correlations. Results: Seven out of 16 PDE11A variants were considered damaging according to in silico predictions: 6 missense variants (p.Tyr727Cys, p.Met623Arg, p.Tyr658Cys, p.Ag867Trp, p.Asn298Ser, p.Glu840Lys) and 1 stop-gain variant (p.Arg307Ter). In the cohort, 11.4% of patients had one of these variants and 19.2% had ARMC5-pathogenic variants. There was no statistically significant difference in the distribution of PDE11A-damaging variants according to ARMC5 status (P = .83; OR = 0.79; 95% CI, 0.26-2.03) nor in the distribution of ARMC5 pathogenic variants according to PDE11A status (P = .83; OR = 0.81; 95% CI, 0.27-2.04). Patients with PDE11A-damaging variants had lower urinary free cortisol (0.7 vs 1.25 upper limit of normal; P = .0002), midnight plasma cortisol (157.81 vs 222.19 nmol/L, P = .016), and number of adrenal nodules (3.46 vs 4.74; P = .048) compared to PDE11A wild-type patients. Patients with ARMC5-pathogenic variants had a more severe phenotype with more frequent comorbidities and were more often treated by adrenalectomy (60%). Conclusion: PDE11A appears to be a modulator of PBMAH phenotype, damaging variants being associated with an attenuated form. This may contribute to the heterogeneity of PBMAH and could affect patient management.
- 7 January 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e2946-e2955
PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series
Context: Primary bilateral macronodular adrenal hyperplasia (PBMAH), the most common cause of Cushing syndrome due to bilateral nodules, is a heterogeneous disease at the clinical, hormonal, and morphological levels. ARMC5-inactivating pathogenic variants are causative of PBMAH, and rare variants of PDE11A have been associated with PBMAH. Objective: The aim of this study, on a large cohort of individuals with PBMAH from Europe and America, was to study the ARMC5 and PDE11A genotype to determine the genotype/phenotype correlation and to investigate the hypothesis that PDE11A could be a modifying gene of the adrenal phenotype. Methods: Leukocyte DNA of 354 PBMAH index cases was sequenced for ARMC5 and PDE11A genes by next-generation sequencing. Phenotypic characteristics of 334 of these patients were analyzed to study the genotype/phenotype correlations. Results: Seven out of 16 PDE11A variants were considered damaging according to in silico predictions: 6 missense variants (p.Tyr727Cys, p.Met623Arg, p.Tyr658Cys, p.Ag867Trp, p.Asn298Ser, p.Glu840Lys) and 1 stop-gain variant (p.Arg307Ter). In the cohort, 11.4% of patients had one of these variants and 19.2% had ARMC5-pathogenic variants. There was no statistically significant difference in the distribution of PDE11A-damaging variants according to ARMC5 status (P = .83; OR = 0.79; 95% CI, 0.26-2.03) nor in the distribution of ARMC5 pathogenic variants according to PDE11A status (P = .83; OR = 0.81; 95% CI, 0.27-2.04). Patients with PDE11A-damaging variants had lower urinary free cortisol (0.7 vs 1.25 upper limit of normal; P = .0002), midnight plasma cortisol (157.81 vs 222.19 nmol/L, P = .016), and number of adrenal nodules (3.46 vs 4.74; P = .048) compared to PDE11A wild-type patients. Patients with ARMC5-pathogenic variants had a more severe phenotype with more frequent comorbidities and were more often treated by adrenalectomy (60%). Conclusion: PDE11A appears to be a modulator of PBMAH phenotype, damaging variants being associated with an attenuated form. This may contribute to the heterogeneity of PBMAH and could affect patient management.